Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

Condition:   Oropharynx Cancer
Interventions:   Drug: Nivolumab;   Radiation: Chemoradiation
Sponsor:   UNICANCER
Not yet recruiting

http://bit.ly/2Ia764e